Pipeline

We are driving forward a pipeline that leverages new targets and cutting-edge modalities to deliver transformative therapies to patients faster.

Filters

Legend: 

The compounds listed are investigational agents; there is no guarantee the agents will receive regulatory approval or become commercially available for the uses being investigated.


Therapeutic Area Name Target Disease Modality Classification Licensor* Phase**

No Results Found

Make sure all words are spelled correctly.


Try different keywords.


Try more general keywords.


*The Compounds with "In-house" in this column include those discovered by collaborative research.

**Compounds are developed globally unless noted. The most advanced development stage is shown for each indication. The right-facing arrow symbol means that the compound has been filed for regulatory approval.

***Approved as "VEOZA" in ex-US.

****Roxadustat ASP1517/FG-4592: Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.

*****ASP546C/XNW27011: Astellas has worldwide rights excluding China's mainland, Hong Kong, Macau, and Taiwan.

******AT132 has been on FDA clinical hold since September 2021.